{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[11,2,11,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910437992603321"]
[null,null,"Titolo",null,"Advances in DNA repair in cancer therapy / / Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Springer, 2013"]
[null,null,"ISBN",null,"1-283-93366-7"]
[{"$nulls":4},"1-4614-4741-0"]
[null,null,"Edizione",null,"[1st ed. 2013.]"]
[null,null,"Descrizione fisica",null,"1 online resource (316 p.)"]
[null,null,"Collana",null,"Cancer drug discovery and development"]
[null,null,"Disciplina",null,"616.99"]
[{"$nulls":4},"616.99/4061"]
[{"$nulls":4},"616.99406"]
[null,null,"Soggetti",null,"Cancer - Treatment - Genetic aspects"]
[{"$nulls":4},"DNA repair"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Preface -- Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy? -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- The relationship between DNA-repair genes, cellular radiosensitivity and the response of tumors and normal tissues to radiotherapy -- Important Roles of ERCC1 in DNA Repair and Targeted Therapy -- The role of BRCA1 and BRCA2 in anticancer drug therapy -- DNA-PK in CLL Chemotherapy -- Poly(ADP) ribose polymerase at the interface of DNA damage signalling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a Therapeutic Target -- Telomeres, Telomerase and DNA Damage Response in Cancer Therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index."]
[null,null,null,"Sommario/riassunto","This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin.  The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1.  Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase "]
[{"$nulls":4},"signalling  is examined."]